Mylan N.V. has launched a bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the UK. Sirdupla is a pressurized metered-dose inhaler (pMDI) and is indicated to help treat or prevent symptoms of asthma in adults 18 years of age and older. The product is being manufactured by 3M Drug Delivery Systems.

3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK. Sirdupla is a daily maintenance pressurized metered-dose inhaler that is available in 125/25 mcg and 250/25 mcg with 120 doses.

Source: Mylan